NADIM ADJUVANT Trial Highlights Advantages of Chemo-Immunotherapy After Surgery in Stage IB–IIIA NSCLC
Interim findings from the NADIM ADJUVANT Phase III clinical trial conducted by the Spanish Lung Cancer Group (GECP) have unveiled ...
Tag: minimal residual disease (MRD)
